Contributions
Abstract: EP1387
Type: ePoster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: MultipleSclerosis (MS) is an inflammatory and degenerative disease of the Central Nervous System, which can present motor, sensory, neuyropsychiatric and cognitive alterations that are characterized by deficits in executive function, memory and visuospatial skills. Few screening useful tools have been validated to detect cognitive impairment in MS.
Objective: The aim of this study was to determine the reliability of the Montreal Cognitive Assessment (MOCA) as screening tool to diagnose cognitive deficit in MS patients.
Methods: Patients with MS according to McDonald 2010criteria, assessed between 2015 and 2016, were included. Those with psychiatric comorbidities were excluded. All subjects were evaluated with MoCA, quality of life scales, and Brief Neuropsychological Battery (BNB), a comprehensive neuropsychological battery validated in Spanish, that include episodic memory assessment, the Symbol-Digit Modalities Test (SDMT), a category fluency test, and the Paced Auditory Serial Addition Test (PASAT). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the curve (AUC) of MoCA were calculated. We also determined the relationship between cognitive impairment and MS subtype. SPSS 20 10.1 was used for the analysis of statistical data.
Results: 52 patients were included, mean age 41,7±11.5 years, 61.5% women, 73,1% with > 10 years of education, and a mean disease duration of 6,0±8,3years. 13 patients showed cognitive impairment according to the MoCA and 9 patients according to the BNB. MoCA showed, with a cut-off point less than 26, a sensitivity, specificity and accuracy of 88,89%, 88,37% and 88% respectively, NPV 97%, PPV 62% and AUC of 0,96 (95%CI 0,90-1,00). We found found significant differences among the scores obtained in the differents groups of MS (Clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS).
Conclusions: MoCA showed a satisfactory level of sensitivity and specificity for detecting cognitive impairment, compared to BNB in MS patients and could be a good screening tool.
Disclosure: Authors declare no conflict of interest
Abstract: EP1387
Type: ePoster
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Introduction: MultipleSclerosis (MS) is an inflammatory and degenerative disease of the Central Nervous System, which can present motor, sensory, neuyropsychiatric and cognitive alterations that are characterized by deficits in executive function, memory and visuospatial skills. Few screening useful tools have been validated to detect cognitive impairment in MS.
Objective: The aim of this study was to determine the reliability of the Montreal Cognitive Assessment (MOCA) as screening tool to diagnose cognitive deficit in MS patients.
Methods: Patients with MS according to McDonald 2010criteria, assessed between 2015 and 2016, were included. Those with psychiatric comorbidities were excluded. All subjects were evaluated with MoCA, quality of life scales, and Brief Neuropsychological Battery (BNB), a comprehensive neuropsychological battery validated in Spanish, that include episodic memory assessment, the Symbol-Digit Modalities Test (SDMT), a category fluency test, and the Paced Auditory Serial Addition Test (PASAT). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), accuracy, and area under the curve (AUC) of MoCA were calculated. We also determined the relationship between cognitive impairment and MS subtype. SPSS 20 10.1 was used for the analysis of statistical data.
Results: 52 patients were included, mean age 41,7±11.5 years, 61.5% women, 73,1% with > 10 years of education, and a mean disease duration of 6,0±8,3years. 13 patients showed cognitive impairment according to the MoCA and 9 patients according to the BNB. MoCA showed, with a cut-off point less than 26, a sensitivity, specificity and accuracy of 88,89%, 88,37% and 88% respectively, NPV 97%, PPV 62% and AUC of 0,96 (95%CI 0,90-1,00). We found found significant differences among the scores obtained in the differents groups of MS (Clinically isolated syndrome, relapsing-remitting MS, secondary progressive MS and primary progressive MS).
Conclusions: MoCA showed a satisfactory level of sensitivity and specificity for detecting cognitive impairment, compared to BNB in MS patients and could be a good screening tool.
Disclosure: Authors declare no conflict of interest